Who are Riboflavin+UV RBC's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/riboflavin-uv-rbc.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Riboflavin+UV RBC — Competitive Intelligence Brief

Riboflavin+UV RBC (Riboflavin+UV RBC) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Pathogen reduction technology / Blood product treatment. Area: Hematology / Transfusion Medicine.

phase 3 Pathogen reduction technology / Blood product treatment Hematology / Transfusion Medicine Biologic Live · refreshed every 30 min

Target snapshot

Riboflavin+UV RBC (Riboflavin+UV RBC) — Federal Research Institute of Pediatric Hematology, Oncology and Immunology. Riboflavin combined with ultraviolet (UV) light exposure inactivates pathogens in red blood cells to reduce transfusion-transmitted infections.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Riboflavin+UV RBC TARGET	Riboflavin+UV RBC	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	phase 3	Pathogen reduction technology / Blood product treatment

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Pathogen reduction technology / Blood product treatment class)

Federal Research Institute of Pediatric Hematology, Oncology and Immunology · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Riboflavin+UV RBC — Competitive Intelligence Brief. https://druglandscape.com/ci/riboflavin-uv-rbc. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab